TruSight Tumor 15

TruSight Tumor 15 uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 15 genes that are commonly mutated in solid tumors. It accurately detects low-frequency variants from 20 ng of starting DNA and is optimized for formalin-fixed, paraffin-embedded (FFPE) tumor tissue. Featuring a rapid workflow that can be easily integrated into lab procedures, this panel offers a single assay for accurate, economical, and rapid analysis of solid tumors.

This TruSight Tumor panel offers:

  • Increased lab efficiency: Comprehensive workflow with detailed QC steps and simple, predefined variant report
  • Enhanced productivity: Rapid turnaround with only 3.5 hours of hands-on time, going from DNA to data in approximately 36 hours
  • Relevant gene content for solid tumors: Somatic variants selected from relevant industry guidelines1,2, key opinion leaders3,4, and pharmaceutical research
  • Sensitive variant detection from low DNA input: Accurate somatic variant detection of 5% allele frequency using 20 ng DNA from FFPE tissue samples

View the gene list »

AKT1 GNA11 NRAS
BRAF GNAQ PDGFRA
EGFR KIT PIK3CA
ERBB2 KRAS RET
FOXL2 MET TP53

TruSight Tumor 15 Sample Datasets

3 human references samples and 5 FFPE-exacted DNA samples from lung, colon, melanoma, and breast tumors were prepared using TruSight Tumor 15 Kit. These libraries were sequenced on the MiniSeq System using a high output kit at a 2 x 150 bp read length configuration with dual indexing. The total yield was 7.6 Gb with 94.9% of bases at or above Q30.

Browse the data in BaseSpace Sequence Hub:

 

For Research Use Only. Not for use in diagnostic procedures.

Product Literature

Description Document Type File Info
Illumina VariantStudio Data Analysis Software Data Sheet PDF2 MB
TruSight Tumor 15 Data Sheet PDF< 1 MB

Catalog IDs: OP-101-1001, OP-101-1002

View the TruSight Tumor 15 support page for additional technical information.

Kit requires MiSeq Software v2.6 or higher and the Illumina Annotation Engine. Download files »

References:

  1. NCCN Clinical Practice Guidelines in Oncology Accessed 15 June 2015.
  2. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii1-9.
  3. Rousseau B, Jacquot C, Le Palabe J, et al. TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in non-small cell lung cancer treatment. Sci Rep. 2015;5:10356.
  4. Haley L, Tseng LH, Zheng G, et al. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers [published online July 31 2015]. Mod Pathol. 2015. doi: 10.1038/modpathol.2015.86.